Intezyne Improves Therapeutic Drug Delivery Efficacy with Wyatt’s DynaPro Plate Reader
News Aug 01, 2008
Wyatt Technology Corporation has announced that Intezyne Technologies has selected the DynaPro Plate Reader to assess the stability of its chemically bespoke drug carriers.
Intezyne Technologies employs the approach in tackling the most important and complex problems associated with targeted therapeutic drug delivery. Active cell targeting permits the selective attachment of the delivery system to diseased areas in the body and is achieved using cell-specific ligands located on the surface of the carrier.
Intezyne Technologies uses a multi-block copolymer design, finely tailored with individual highly specific polymers to address key problems such as drug-carrier stability. The effects of surrounding pH, ionic charge, temperature and chemical concentrations on constructed carriers are key in effective target-specific drug therapy.
The only way to attain this critical information is by monitoring the interactions of the drug carriers in acutely graded environments. This requires the processing of thousands of Dynamic Light Scattering (DLS) experiments as quickly as possible.
Intezyne Technologies acquired a Wyatt Technology DynaPro Plate Reader DLS instrument, whose disposable well plates removed the need for individual cuvettes. This plate reader technology removed the normal transfer stage from Intezyne Technologies’ serum-stability experiments, reducing a process that took scientists up to 16 hours down to just five minutes.
Bypassing the arduous process of individually preparing and reading each concentration removed the risk of contamination of samples and inaccuracies that could be caused by fingerprints through the transfer of samples and repeat experiments. Also because the Plate Reader avoids “sucking and sipping” technologies that require sample handling and transfer, Intezyne also avoided potential cross-contamination of their samples.
The 96 well-plate format proved ideal for Intezyne Technologies for pipetting out the required graded concentrations, allowing experiments with a spectrum of conditions to be carried out and comparisons made with Wyatt’s SpectralView software.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE